Transcriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance.

"Declarations Ethics approval and consent to participateThis research was approved by the Ethics Committee of the First Affiliated Hospital of Ningbo University, and every individual signed a written informed consent form before the study was initiated. Consent for publicationAll the persons were consent for publication in this journal. Competing interestsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests. Competing interests The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests."

"Funding The study was supported by the Zhejiang Provincial Natural Science Foundation of China (TGY24H020009), the Project of Science and technology on Medicine and Health in Zhejiang Province (2022KY312), the Project of Science and Technology on Traditional Chinese Medicine in Zhejiang Province (2022ZB322 and 2023ZL158), Ningbo Municipal Public Welfare Project (2021S109), the Key Technology R and D Program of Ningbo (2022Z149), and the Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province (2022E10026)."